.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Harvard Business School
Daiichi Sankyo
US Army
Queensland Health
Baxter
Medtronic
Cantor Fitzgerald
Merck
Boehringer Ingelheim

Generated: December 18, 2017

DrugPatentWatch Database Preview

Isavuconazonium sulfate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for isavuconazonium sulfate and what is the scope of isavuconazonium sulfate patent protection?

Isavuconazonium sulfate
is the generic ingredient in one branded drug marketed by Astellas and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Isavuconazonium sulfate has twenty-four patent family members in nineteen countries and nine supplementary protection certificates in eight countries.

One supplier is listed for this compound.

Summary for isavuconazonium sulfate

US Patents:2
Tradenames:1
Applicants:1
NDAs:2
Suppliers / Packagers: 1
Clinical Trials: 661
Drug Prices:see low prices
DailyMed Link:isavuconazonium sulfate at DailyMed

Pharmacology for isavuconazonium sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
AstellasCRESEMBAisavuconazonium sulfatePOWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfateCAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfateCAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfatePOWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfatePOWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfatePOWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfateCAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
AstellasCRESEMBAisavuconazonium sulfateCAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
AstellasCRESEMBAisavuconazonium sulfatePOWDER;IV (INFUSION)207501-001Mar 6, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
AstellasCRESEMBAisavuconazonium sulfateCAPSULE;ORAL207500-001Mar 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: isavuconazonium sulfate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,151,182Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives► Subscribe
7,189,858N-phenyl substituted carbamoyloxyalkyl-azolium derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: isavuconazonium sulfate

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0132652► Subscribe
Canada2680292► Subscribe
Australia2835201► Subscribe
Australia777859► Subscribe
Denmark1280795► Subscribe
Netherlands300791► Subscribe
China1185230► Subscribe
Turkey200201205► Subscribe
Spain2238341► Subscribe
Japan3787307► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ISAVUCONAZONIUM SULFATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0096France► SubscribePRODUCT NAME: ISAVUCONAZOLE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
0791Netherlands► SubscribePRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUM SULFAAT OF ALS EEN ISAVUCONAZONIUM ZOUT MET ELK ANDER FARMACEUTISCH AANVAARDBAAR ANION, NAAR KEUZE IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/15/1036 20151019
2Finland► Subscribe
2016000011Germany► SubscribePRODUCT NAME: ISAVUCONAZONIUM ALS ISAVUCONAZONIUM-SULFAT ODER ALS SALZ MIT EINEM ANDEREN PHARMAZEUTISCH VERTRAEGLICHEN ANION, SOWIE HYDRATE ODER SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/15/1036 20151015
939Luxembourg► SubscribePRODUCT NAME: ISAVUCONBAZOLE EN TANT QUE SULFATE D'ISAVUCONAZONIUM OU EN TANT QUE SEL D'ISAVUCONAZONIUM AVEC TOUT AUTRE ANION PHARMACEUTIQUEMENT ACCEPTABLE, OPTIONNELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151019
2014000122Germany► SubscribePRODUCT NAME: SITAGLIPTIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
90011-0Sweden► SubscribePRODUCT NAME: ISAVUCONAZOLE; REG. NO/DATE: EU/1/15/1036 20151016
15/073Ireland► SubscribePRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
2016 00002Denmark► SubscribePRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS AN ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REG. NO/DATE: EU/1/15/1036 20151019
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chubb
McKinsey
Mallinckrodt
Fish and Richardson
Baxter
Boehringer Ingelheim
Fuji
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot